SafePlate’s device offers the first real-time, in-house quantitative allergen test, bringing laboratory-level analysis directly to food manufacturers. This innovative device delivers three primary value propositions: rapid testing with laboratory-grade accuracy, real-time quantitative results, and multiplex testing capabilities. Reducing lab test wait times from between twenty-four hours and two weeks to just ten minutes drastically lowers manufacturers’ holding costs. The availability of quantitative data enables food safety professionals to identify trends, optimize testing strategies, and enhance preventive measures to combat contamination and recalls. Multiplex testing further increases efficiency and cost-effectiveness by consolidating multiple contaminants tests into a single, streamlined process. 

SafePlate’s device presents a highly attractive business model centered on its proprietary testing device. The device will cost $5,000 to manufacture and will be priced at $10,000 per unit, a strategic price point designed to be accessible to small and mid-sized manufacturers while remaining competitive for large-scale operations. This sell price may increase after the company sells its first few units and no longer needs beachhead pricing to break the novel solution into the market. However, this current pricing places the device in the middle of the market spectrum—high enough to reflect the advanced technology and value it provides, yet low enough to encourage adoption across manufacturers of varying sizes. By maintaining a reasonable upfront cost, financial barriers that often prevent smaller companies from investing in high-quality food safety solutions are minimized, while affordability is ensured for larger manufacturers looking to scale testing across multiple lines. 

Instead of relying heavily on hardware sales, the revenue model is structured around daily consumable electrodes, essential for device operation, priced at $100 per day and projected to cost $20 to manufacture (while currently only costing the team $13 to produce). This approach ensures that the majority of revenue comes from ongoing usage rather than a high initial investment in hardware, making the system financially viable for companies of all sizes. The daily consumable model not only provides a stable, recurring revenue stream throughout all seasons but also encourages frequent testing without cost constraints. Additional costs for the customer come from consumable reagents provided in containers that can be sent back to SafePlate to be refilled, with the volume of reagents used per test costing mere cents (currently costing us 29¢ and easily costing less by buying reagents in bulk in the future). The team plans to supply the manufacturer with enough reagents to last a month of food manufacturer’s testing schedule, and the additional cost of producing and buying such reagents should not be significant to the SafePlate team or the purchasing food manufacturer, respectively. 

Compared to existing allergen testing solutions, this device offers a cost-effective and scalable alternative. Single-use allergen swab tests, commonly used in food manufacturing despite their lower reliability and pass/fail results only, typically cost between $10 and $15 per test, with facilities often conducting multiple tests per production shift. At an average of 10 tests per day, swab testing costs can exceed $36,000 annually for a single production line. However, some manufacturers conduct 50 or more tests per day, pushing annual costs above $100,000, with others still confirming to the team that they conduct up to 250 tests per day. Third-party lab testing, another common method, ranges from $150 to $300 per test, often with turnaround times of several days and may total $5,000 - $10,000 dollars per batch of product tested. In contrast, this device enables rapid, in-house testing at a significantly lower per-test cost while eliminating delays associated with external lab processing. 

With consistent use, the SafePlate system quickly becomes cost-effective. For example, at just five tests per day, the device and consumables cost approximately $36 per test over the first year, dropping to $20 per test in subsequent years (once the initial device cost is already accounted for)—far below the cost of outsourcing to labs and competitive with high-frequency swab testing. For manufacturers conducting 20 tests per day, the cost per test is reduced even further, leading to significant long-term savings. At this testing frequency, SafePlate’s solution comes out to $5.29 per test for the daily consumable and reagents (assuming the device’s cost is already accounted for), noticeably lower than the $10 cost of swab tests. This price drops even further with volume, costing only $2.79 per test if 40 tests are run on the device. This pricing strategy maximizes adoption while creating a sustainable, scalable business model that supports manufacturers of all sizes in maintaining rigorous food safety standards. 

SafePlate Technologies operates within a niche competitive landscape dominated by startups and existing allergen testing solutions. Legacy industry players have yet to integrate emerging technologies or effectively address new market demands. SafePlate aims to bring the benefits of lab grade testing to the manufacturer’s facility with the ease and speed of the current lateral flow test that is used by manufacturers to test (somewhat unreliably) for allergens. Accurate and quantitative data is more useful than the pass/fail results given by current lateral flow tests, as this data can be used to identify trends that can preemptively prevent food safety disasters and recalls. The device is also a major improvement over sending samples for 3rd party lab testing,  as the device will deliver sophisticated results within 10 minutes as opposed to 24-48 hours of lab testing, and the device will be operable with no technical expertise which is a large hurdle a food manufacture would encounter if opening a full analytical lab in their factory. The team is planning on adapting the device to integrate with current food safety software programs on the market, allowing this data to seamlessly upload and integrate into these programs. When expanding to pathogen testing (which is the next priority), SafePlate aims to adapt the already proven sensor and device technology to address many of the current shortcomings in the pathogen testing industry. First, the company aims to be the first test to obtain lab-grade results in less than one hour. The only way this is currently possible is by obtaining results without the need for enriching pathogen cells or DNA, which would also make the testing process much safer to conduct within a food manufacturing facility. The level of automation would be carried over from the gluten testing device, and multiplexing of electrodes would allow the same device to test for allergens and pathogens, essentially creating a universal testing device (with plans to expand to other contaminants in the future).

 

The initial target market is the U.S. gluten-free testing sector, valued at approximately $100 million. Market validation has been conducted through three primary channels. First, the team has engaged in over 100 direct interviews with food safety professionals across more than 75 food manufacturing companies, gaining critical insights into industry needs. Second, attendance at key industry conferences, including the Food Safety Consortium in the Fall of 2024, has provided additional validation through interactions with industry experts and stakeholders. Third, direct discussions with the two largest players in the food safety test manufacturing market have confirmed a strong demand for faster, more accurate testing methods, with expressed interest in investment contingent upon further technological development. These contacts have continued to stay in touch and have stated that acquisition is a strong possibility if a robust device emerges from the team’s research. 

The company’s commercialization strategy follows a phased approach: establishing technical credibility through successful demonstrations, penetrating the market via pilot programs and trade shows, and scaling adoption among industry leaders. Upon completion of a factory-ready prototype, SafePlate Technologies will initiate 90-day pilot programs within the gluten-free manufacturing sector, with one rice flour producer already committed to early adoption. Following successful validation, market penetration will expand through industry journal publications (e.g., Journal of Food Protection) and participation in major food safety trade shows (e.g., Food Safety Summit). 

Technology validation for the project will be done through a study conducted by the Association of Official Analytical Collaboration (AOAC). Completion of this study will enable regulatory approval and market readiness. Simultaneously, rigorous internal validation protocols will ensure benchmark accuracy and reliability, minimizing the risk of false results and ensuring consumer safety.